• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Instituto de Ciências Ambientais, Químicas e Farmacêuticas (ICAQF)
  • ICAQF - Artigos
  • View Item
  •   DSpace Home
  • Instituto de Ciências Ambientais, Químicas e Farmacêuticas (ICAQF)
  • ICAQF - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Topical and cutaneous delivery using nanosystems

Thumbnail
Date
2017
Author
Roberts, M. S.
Mohammed, Y.
Pastore, M. N.
Namjoshi, S.
Yousef, S.
Alinaghi, A.
Haridass, I. N.
Abd, E.
Leite-Silva, V. R. [UNIFESP]
Benson, H. A. E.
Grice, J. E.
Type
Artigo
ISSN
0168-3659
Is part of
Journal Of Controlled Release
DOI
10.1016/j.jconrel.2016.12.022
Metadata
Show full item record
Abstract
The goal of topical and cutaneous delivery is to deliver therapeutic and other substances to a desired target site in the skin at appropriate doses to achieve a safe and efficacious outcome. Normally, however, when the stratum corneumis intact and the skin barrier is uncompromised, this is limited to molecules that are relatively lipophilic, small and uncharged, thereby excluding many potentially useful therapeutic peptides, proteins, vaccines, gene fragments or drug-carrying particles. In this review we will describe how nanosystems are being increasingly exploited for topical and cutaneous delivery, particularly for these previously difficult substances. This is also being driven by the development of novel technologies, which include minimally invasive delivery systems and more precise fabrication techniques. While there is a vast array of nanosystems under development and many undergoing advanced clinical trials, relatively few have achieved full translation to clinical practice. This slow uptake may be due, in part, to the need for a rigorous demonstration of safety in these new nanotechnologies. Some of the safety aspects associated with nanosystems will be considered in this review. (C) 2016 Elsevier B.V. All rights reserved.
Citation
Journal Of Controlled Release. Amsterdam, v. 247, p. 86-105, 2017.
Keywords
Topical delivery
Cutaneous delivery
Nanosystems
Nanoparticles
Colloidal nanocarrier systems
Sponsorship
National Health and Medical Research Council of Australia
US FDA grants
URI
https://repositorio.unifesp.br/handle/11600/55107
Collections
  • ICAQF - Artigos [1142]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV